The new Faecal Calprotection Care Pathway
Please note: this is no longer an active Health Innovation Manchester Project
IBS affects between 10-20% of the population with 95% of patients being referred unnecessarily for secondary care.
Faecal Calprotectin is a Biomarker that is used to help differentiate between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Syndrome (IBD). Current processes are causing unnecessary treatment for those patients with IBS, impacting on resources, cost and outcomes on patient experience.
The new pathway supports CCGs and GPs in decision-making to refer or treat. Resources have been produced to provide CCGs, GPs and Trusts to ensure the pathway is utilised and implented.
The aim of this project is to improve pathway of treatment for IBS and IBD patients through faecal calprotectin testing by:
– Developing an implementation plan for roll-out of the pathway into the local areas.
– Utilising and adopting resources for CCG and GPs to use.
The potential impacts and outcomes of this programme could see a reduction in hospital admissions for secondary care, reduced waiting times in endoscopy and gastroenterology, money saved across the NHS from the reduction of unnecessary treatment and an overall better patient experience.